ERT

Jazz, Concert partner to develop deuterium-modified sodium oxybate

Wednesday, February 27, 2013 11:54 AM

Jazz Pharmaceuticals, an Irish specialty biopharmaceutical company focused on unmet medical needs, and Concert Pharmaceuticals, a Lexington, Mass.-based clinical stage biotechnology company, have signed an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.   

More... »

RWJF awards $1.9M grant to PatientsLikeMe

Monday, February 25, 2013 11:26 AM

PatientsLikeMe, a patient network that improves lives and a real-time research platform that advances medicine, has been awarded a $1.9 million grant from the Robert Wood Johnson Foundation (RWJF) to create the world's first open-participation research platform for the development of patient-centered health outcome measures.

More... »

Synteract appoints Kelson as CFO, Doren as vice president of biometrics

Wednesday, January 30, 2013 03:18 PM

Synteract, a full service CRO based in Carlsbad, Calif., has hired new executives to support customers on a global scale. Keith Kelson will serve as chief financial officer and member of its executive council, and Phil Doren has been appointed vice president of biometrics.

More... »

ERT expands corporate presence in Japan

Wednesday, January 16, 2013 09:26 AM

ERT, a global technology-driven provider of health outcomes research services, has completed registration for Kabushiki Kaisha (KK) in Japan and has formed a fully-owned subsidiary, ERT Asia Group.

More... »

AAIPharma appoints Browne as director of analytical chemistry

Wednesday, December 5, 2012 11:02 AM

AAIPharma Services, a provider of pharmaceutical product development services, has appointed David Browne as the company's director of analytical chemistry for its Edison, N.J., laboratory.

More... »

Vertex, GSK partner on phase II all-oral study of VX-135, GSK2336805 for Hep C

Friday, November 2, 2012 11:23 AM

Vertex Pharmaceuticals, a global biotechnology company based in Cambridge, Mass., has entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue HCV polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805.

More... »

SpringFire Laboratory Network adds ReproSource to affiliate laboratories

Friday, October 19, 2012 10:32 AM

SpringFire Laboratory Network, a network of independent, esoteric, high complexity laboratories, has added ReproSource Fertility Diagnostics, a Boston-based clinical laboratory and research organization that provides solutions for fertility testing and education, to its network of affiliate laboratories, which provides specialized testing services to clinical trial sponsors and CROs.

More... »

Eckert & Ziegler acquires Vitalea Science

Tuesday, September 11, 2012 11:25 AM

Germany-based Eckert & Ziegler Strahlen- und Medizintechnik, through its Californian subsidiary Eckert & Ziegler Isotope Products (EZIP), has agreed to purchase all stock and assets of Vitalea Science. Vitalea Science is a bioanalytical CRO that provides services to researchers and clinicians in drug development supported by validated Accelerator Mass Spectrometry (AMS) technologies.

More... »

ERT launches enhanced platform to streamline data collection, analysis and processing

Friday, September 7, 2012 11:57 AM

ERT, a global technology-driven provider of health outcomes services, has launched an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials.

More... »

ERT introduces enhanced platform to streamline clinical trial data collection

Tuesday, August 28, 2012 12:31 PM

Philadelphia-based ERT, a global provider of health outcomes services, has launched an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials. The new offering, which comprises the EXPERT3 workflow platform and MyStudyPortal3 reporting engine, can simultaneously process health outcomes data across cardiac safety, Clinical Outcome Assessment (COA)/ePRO and respiratory studies. The platform offers users a simple way to process multiple types of data accurately, leading to fewer errors in studies.

More... »